Jim Cramer shares his views every day on RealMoney. Click here for a real-time look at his insights and musings.
Cramer: Avoid Sloppiness by Watching Your Stock Table Manners
Posted at 2:58 p.m. EDT on Thursday, May 26, 2016
When the market is as spectacular as this one has been of late, people get carried away. They take to heart that the averages hang in there after a couple of really good days, and they decide to get sloppy.
So I want to give you some lessons in sloppiness so you maintain your stock table manners.
First thing that happens? People see takeovers everywhere. Case in point? There was a report in The Financial Times this morning that Apple (AAPL) has been in talks to acquire Time Warner (TWX) . At the same time, chatter made its way around the floor of the stock exchange where I work in the mornings, that Apple is eying Netflix (NFLX) .
Now, long-term viewers and readers know that I advocated for Apple, which is part of my Action Alerts PLUS charitable portfolio, to buy Netflix when it was half the price because that earnings stream would be so fabulous to have. I watch all my Netflix shows on my iPad Pro. It would be so easy to have everything Apple come with a Netflix button. It would make life too easy. And I would keep Reed Hastings, the man behind so much of what is fabulous about the company.
Time Warner is a fabulous enterprise. Buried within the company is an asset that would fit the service revenue stream I love about Apple to a T--the wondrous HBO.
But if you bought either of these two stocks because of this rumor when the stocks were running this morning, you need to call a time out. You need to cool off. Go get an ice cream or something. I mean, really, that's Exhibit A in sloppiness.
Next example: trading off of oil. I have said over and over again, beginning in the $30s that when oil gets to $50 it is most likely going to run out of steam. That's because $50 is where many oil companies profitably can sell oil futures to bring in extra income to forestall the grim banking reaper. That means the supply that's been missing in the U.S., the oil that's been throttled back because too much money was being lost drilling for it, can come back on the market. So if you have been riding oil, buying stocks because you thought you were safe as long as oil went up, you are going to find yourself in a house of pain if I am right about my thesis.
Yep, there are still many hedge funds that are set up to buy stocks when oil goes higher and sell them when crude goes lower so you very well may be caught playing musical oil chairs. Now if you know what you own and oil goes down and it takes your stock with it, then you can buy more. But if you are sloppy you will have bought high and sold low.
The third example of sloppiness? I have been telling you that we are not in a market where you can speculate on stocks without earnings. It is way too dicey. That game ended a long time ago. The companies that have stocks that are doing well in this environment are ones with faster growth but rock-ribbed balance sheets and buybacks or dividends. Sure, there are a couple of outliers like Saleforce.com (CRM) that look like they are very expensive and are very fast-growing. But if you look underneath the hood, you will see that Salesforce.com has a gigantic amount of cash flow; it just likes to reinvest in the business because it is so fast-growing.
What's an example of rank speculation? A stock I have been saying for weeks now doesn't have a chance in this environment is Ionis Pharmaceuticals (IONS) , the old Isis, which today was pummeled by almost 40% when one of its key drugs lost the support of partner Glaxo (GSK) , which decided not to start a final-stage study for the compound.
There was a time when owning an Ionis was reasonable; the market liked companies with the possibility of a winning drug that, if the study went well, might be snapped up by a Glaxo the way Celgene (CELG) snapped up Receptos after that target had some excellent results in some key drugs. However, I have been saying you have to respect the tape we are in, so to speak, and recognize that the risk/reward has changed radically for those companies with no earnings streams and the hope of a new drug.